News coverage about Second Sight Medical Products (NASDAQ:EYES) has been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Second Sight Medical Products earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned media coverage about the medical device company an impact score of 44.3130215154554 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
A number of equities analysts have recently weighed in on the company. Zacks Investment Research upgraded Second Sight Medical Products from a “sell” rating to a “hold” rating in a research note on Monday. HC Wainwright set a $5.00 target price on Second Sight Medical Products and gave the stock a “buy” rating in a research note on Tuesday, October 17th.
Shares of Second Sight Medical Products (NASDAQ:EYES) traded up $0.03 during midday trading on Thursday, hitting $2.00. The stock had a trading volume of 246,106 shares, compared to its average volume of 504,326. The stock has a market cap of $113.04, a P/E ratio of -2.99 and a beta of 3.71. Second Sight Medical Products has a 12-month low of $0.90 and a 12-month high of $2.83.
Second Sight Medical Products (NASDAQ:EYES) last posted its quarterly earnings results on Thursday, November 2nd. The medical device company reported ($0.12) EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.02. The company had revenue of $1.61 million for the quarter, compared to analysts’ expectations of $1.54 million. Second Sight Medical Products had a negative net margin of 565.12% and a negative return on equity of 184.87%. research analysts anticipate that Second Sight Medical Products will post -0.55 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: This piece was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another publication, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/11/second-sight-medical-products-eyes-given-media-impact-score-of-0-13.html.
About Second Sight Medical Products
Second Sight Medical Products, Inc is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight.
Receive News & Ratings for Second Sight Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products and related companies with MarketBeat.com's FREE daily email newsletter.